ONCOLOGY FOCUS

Personal & Precise | Personalized Medicine, Precision Medicine, Genomics, Tumor Typing, Genetic Mutation, Sarah Cannon Research Institute, SCRI, Holli Dilks, Andy Corts, Syapse
Personal & Precise

The Continued Push Toward Targeted Therapies

In his recent State of the Union address and again a few days later at the White House, President Barack Obama outlined his $215 million Precision Medicine Initiative.


CINDY SANDERS

Best Case Scenarios | DiaTech Oncology, Cancer Profiling, Apoptosis, Cancer Cell Death, CorrectChemo, Microculture-Kinetic Assay, MiCK Assay, Vanderbilt University, Robert Henry
Best Case Scenarios

CorrectChemo Measures Cancer’s Response to Therapeutic Agents

While the patented technology might be complex, the premise behind it is straightforward … not every chemotherapy agent is equal in every patient.


CINDY SANDERS

By the Numbers: The Latest Stats on Cancer | Cancer, Oncology, Cancer Death Rates, Mortality Rates, American Cancer Society, Cancer Facts & Figures 2015, Lung Cancer, Breast, Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Margaret Foti, Julie Fleshman, John Seffrin, Precision Medicine Initiative
By the Numbers: The Latest Stats on Cancer

Death rates down, more work awaits

As the ‘official sponsor of birthdays,’ the American Cancer Society (ACS) found a reason to rejoice in their latest report – Cancer Facts & Figures 2015.


CINDY SANDERS

ONcology Rounds: Prostate Cancer | Prostate Cancer, Dr. William Mitchell, Liquid Biopsy, Dr. David Morris, Urology Associates, UroNav, Invivo, MR/US Fusion Biopsy
ONcology Rounds: Prostate Cancer

Urology Associates Offering New Fusion Biopsy

Urology Associates, PC, introduced targeted MR/US fusion biopsy in late January, becoming the first urology practice in the state to offer the new technology to patients with elevated and/or rising PSA levels.


CINDY SANDERS

ONcology Rounds: Breast Cancer

New Drug Seen as Possible ‘Game Changer’

Last month, Pfizer Inc. received Food and Drug Administration accelerated approval of Ibrance® (palbociclib) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as first-line endocrine-based therapy for their metastatic disease.


CINDY SANDERS